

FOI REF: 26/285

20th May 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I would be grateful if you could tell me how many patients were treated between January and March 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

- 1) How many patients were treated in total regardless of diagnosis with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?**

Drug Name	Total number of patients treated regardless of diagnosis
Adalimumab	836
Etrasimod	0
Filgotinib	21
Golimumab	27
Guselkumab	15
Infliximab (Biosimilars)	248
Infliximab (Remicade)	7
Mirikizumab	9
Ozanimod	2
Risankizumab	46
Tofacitinib	19
Upadacitinib	86
Ustekinumab	335
Vedolizumab	136

- 2) How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the Gastroenterology Department
Adalimumab	258
Etrasimod	0
Filgotinib	7
Golimumab	1
Guselkumab	5
Infliximab (Biosimilars)	121
Infliximab (Remicade)	3
Mirikizumab	9
Ozanimod	2
Risankizumab	35
Tofacitinib	4
Upadacitinib	49
Ustekinumab	207
Vedolizumab	126

- 3) How many patients with Crohn's Disease or Ulcerative Colitis, in total regardless of department / clinic, were treated with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with Crohn's Disease	Number patients with Ulcerative Colitis
Adalimumab	174	90
Etrasimod	0	0
Filgotinib	0	8
Golimumab	0	1
Guselkumab	4	2
Infliximab (Biosimilars)	80	56
Infliximab (Remicade)	5	0
Mirikizumab	0	8
Ozanimod	0	2
Risankizumab	37	0
Tofacitinib	0	2
Upadacitinib	30	20
Ustekinumab	171	41
Vedolizumab	58	76

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm